Search Results (2)

The complexity of Alzheimer’s disease (AD) pathophysiology represents a significant challenge in the development of effective therapeutic agents for its treatment. CNEURO-201 (CN, also Amylovis-201) is a novel pharmaceutical agent with dual activity as an anti-amyloid-β (Aβ) agent and σ1 receptor agonist. CN exhibits great efficacy at very low doses, delaying cognitive impairment and alleviating Aβ load in animal models of AD. However, CN functions on other remains related to this pathology remain to be investigated. The present study sought to evaluate the effects of CN treatment at a dosage of 0.1 mg kg⁻¹ (p.o) over an eight-week period in the 3xTg-AD mouse model. In silico studies, as well as biochemical and immunofluorescence assays, were conducted on brain tissue to investigate the CN effects on acetylcholine metabolism, redox system, and glial cell activation-related biomarkers in brain regions that are relevant for memory. The results demonstrated that CN effectively rescues cognitive impairment of 3xTg-AD mice by influencing glial activity to reduce existing Aβ plaques but also modulating acetylcholine metabolism and the enzymatic response of proteins involved in the redox system. Our outcomes reinforced the potential of CN in treating AD by acting on multiple pathways altered in this disease. Full article

Iron oxide nanoparticles (IONPs) have high relativity for Magnetic Resonance Imaging (MRI) and have shown a long half-life which can covalently bind with drugs and antibodies that can be used for increased contrast while imaging with MRI. IONPs are approved by the U.S Food and Drug Administration to be used as a contrast agent for MRI in vivo. The Cuban Neuroscience Center has developed a new family of naphthalene derivative compounds called Amylovis^® to be used to diagnose and treatment of Alzheimer’s disease (AD). The goal of this work is to synthesize IONPs with different coatings to be conjugated to Amylovis^® as contrast agents for MRI. Coprecipitation method was employed to obtain the magnetic nuclei, and two synthesis methodologies were performed to coat the IONPs (post-synthesis or in situ). The different coatings used were the following: (3-aminopropyl)triethoxysilane (APTES), dicarboxylic polyethyleneglycol, galic acid, polyacrylic acid and citrate. Carbodiimide method was used as synthetic protocol to conjugate the Amylovis^® moiety to different coatings. The nanoparticles were characterized by DRX, FT-IR, Electrophoretic Light Scattering (ELS) and Dynamic Light Scattering (DLS). Moreover, the stability of nanoparticles in water was evaluated using a sedimentation curve. In order to determine the potential interaction of nanosystems with the beta amyloid peptides, a molecular docking was carried out. The theoretical study showed that coatings do not affect the interaction of Amylovis^® with the receptor, and the new polar groups incorporated increased the affinity to receptor. Full article